Efficacy and Safety of Pulse Intravenous Methylprednisolone in Pediatric Epileptic Encephalopathies: Timing and...

Area of Science:

• Pediatric Neurology
• Epileptology
• Clinical Pharmacology

Background:

• Epileptic encephalopathies (EE) present with severe, drug-resistant seizures, early onset, and poor developmental trajectories.
• Intravenous methylprednisolone (IVMP) pulse therapy is explored for its potential in managing pediatric EE.
• Evaluating the efficacy and tolerability of IVMP is crucial for treatment optimization in this population.

Purpose of the Study:

• To assess the efficacy and tolerability of intravenous methylprednisolone (IVMP) pulse therapy in pediatric patients diagnosed with epileptic encephalopathies (EE).
• To identify predictors of favorable outcomes following IVMP treatment.
• To evaluate the impact of IVMP on patients' quality of life (QoL).

Main Methods:

• Retrospective study conducted between 2020 and 2023.
• Inclusion criteria: pediatric patients (≤18 years) receiving IVMP pulse therapy with a minimum 6-month follow-up.
• Efficacy measured by >50% seizure reduction (responder rate) at 6 and 9 months of therapy, and 6 months post-therapy; QoL assessed.

Main Results:

• A responder rate of 85.7% at 6 and 9 months, and 80.9% at 6 months post-therapy suspension was observed in 21 pediatric patients.
• Favorable outcomes were significantly predicted by etiology and epilepsy type, with genetic epilepsy and ESES showing the best results.
• All patients reported improved QoL, with no significant adverse events noted during IVMP treatment.

Conclusions:

• IVMP pulse therapy demonstrates significant efficacy and high tolerability in pediatric patients with EE.
• Genetic epilepsy and electrical status epilepticus during slow-wave sleep (ESES) are positive predictors for favorable clinical outcomes.
• Early consideration of IVMP pulse therapy is recommended for patients with EE, given the observed improvements in QoL, EEG, and motor development.